Biotech startups operate in a uniquely challenging environment. Between securing funding, navigating FDA regulations, and racing toward clinical milestones, employment law often falls to the bottom of the priority list. Yet these oversights can result in costly litigation, damaged reputations, and distracted leadership teams at the worst possible moments.

Through extensive research of employment law cases in the life sciences sector, we’ve identified five critical mistakes that repeatedly emerge in biotech companies. Here’s what you need to know to protect your company.

1. Misclassifying Scientific Staff as Exempt Employees

The Mistake: Many biotech startups automatically classify research associates, lab technicians, and junior scientists as exempt from overtime pay, assuming their scientific work qualifies them for the “learned professional” exemption under the Fair Labor Standards Act (FLSA).

Why It’s Dangerous: The reality is more nuanced. While senior scientists with advanced degrees making independent judgments may qualify as exempt, many lab personnel performing routine protocols, data collection, or quality control work likely don’t meet the legal threshold.

Real Case Example: In 2019, pharmaceutical company Novartis paid $99.5 million to settle a class action lawsuit where sales representatives claimed they were misclassified as exempt employees. While not a small biotech, this case illustrates the massive financial risk. Similarly, Quest Diagnostics paid $1.37 million in 2014 to settle wage claims from phlebotomists and lab assistants who were improperly classified as exempt.

The Solution: Conduct a thorough job duties analysis for each position, not just job titles. Focus on the actual work performed daily, the level of independent judgment exercised, and whether the role truly requires advanced knowledge in a field of science. According to the Department of Labor’s guidance, the exemption requires that employees exercise “consistent discretion and judgment” in performing their duties. When in doubt, classify positions as non-exempt. The cost of paying overtime is almost always less than the cost of defending a wage-and-hour lawsuit.

2. Using Overly Broad or Unenforceable IP Assignment Agreements

The Mistake: Biotech founders understandably want to protect their intellectual property, so they often draft or copy IP assignment agreements that claim ownership of everything an employee creates, “whether or not related to the company’s business,” sometimes even including work done before employment or on personal time.

Why It’s Dangerous: Several states, including California (home to many biotech hubs), have laws that limit what IP employers can claim. California Labor Code Section 2870 prevents companies from claiming ownership of inventions employees develop on their own time without company resources, unless the invention relates to the company’s business or results from work performed for the company.

Real Case Example: In Edwards v. Arthur Andersen LLP (2008), a California court invalidated portions of an IP agreement that violated Section 2870. While this wasn’t a biotech case specifically, it established important precedent. More recently, several biotech companies have faced disputes when founders or early employees left to start competing companies, claiming their new innovations were developed independently. These cases often settle confidentially but involve significant legal costs and business disruption.

The Solution: Work with employment counsel to draft IP agreements that comply with state law while still protecting your core interests. Be specific about what you’re protecting. Focus on inventions that relate to your actual or demonstrably anticipated business, or that result from work performed with company resources. This approach is both legally sound and more likely to hold up if challenged.

3. Failing to Properly Document Performance Issues Before Termination

The Mistake: When a scientist or team member isn’t performing, biotech leaders often handle it informally through conversations, hoping the situation improves. When it doesn’t and termination becomes necessary, there’s little or no documentation to support the decision.

Why It’s Dangerous: Without a clear paper trail, a termination that was genuinely performance-based can look like discrimination or retaliation, especially if the employee is in a protected class or recently engaged in protected activity like requesting FMLA leave or raising safety concerns.

Real Case Example: Genentech faced a $6.8 million jury verdict in 2014 when a former employee claimed age discrimination after being terminated. The employee was 61 years old and argued that performance issues cited weren’t properly documented and that younger employees with similar issues weren’t terminated. In 2016, Biogen paid $250,000 to settle an EEOC lawsuit alleging that a quality control manager was fired in retaliation for reporting safety concerns, with inadequate documentation of the stated performance reasons.

The Solution: Implement a consistent performance management system early. Document performance conversations, provide written feedback, and create performance improvement plans when issues arise. According to SHRM (Society for Human Resource Management), contemporaneous documentation is critical evidence in defending employment claims. This doesn’t mean you need heavy bureaucracy, but you do need contemporaneous records that show you gave employees clear expectations, feedback, and opportunities to improve.

4. Neglecting Accommodation Obligations for Employees with Disabilities

The Mistake: Biotech work often involves physical lab work, precise manual tasks, and exposure to chemicals or biological materials. When an employee requests an accommodation, leaders sometimes conclude too quickly that the essential functions of the job can’t be modified, particularly in a small startup environment with limited resources.

Why It’s Dangerous: The Americans with Disabilities Act (ADA) requires employers to engage in an interactive process to identify reasonable accommodations, and what constitutes “reasonable” is often broader than employers expect.

Real Case Example: In 2017, biotechnology company Illumina paid $325,000 to settle an EEOC lawsuit alleging they failed to accommodate an employee’s disability and then retaliated against her. The EEOC found that the company failed to engage in a good-faith interactive process. In another case, pharmaceutical manufacturer Endo Health Solutions paid $1.8 million in 2015 to settle claims that it failed to accommodate employees with disabilities and instead terminated them.

According to the EEOC, failure to engage in the interactive process is one of the most common ADA violations, and the agency has prioritized enforcement in scientific and healthcare industries.

The Solution: When an employee discloses a disability or requests an accommodation, initiate an interactive dialogue immediately. Ask what limitations the employee is experiencing and what accommodations they believe would help. Consider options like modified schedules, ergonomic equipment, reassignment of marginal job functions, or temporary adjustments during treatment. Document the entire interactive process. Even if you ultimately can’t accommodate the request, demonstrating that you engaged seriously and explored alternatives in good faith provides significant legal protection.

5. Inadequate Equity Compensation Documentation and Communication

The Mistake: Equity is often the currency that allows biotech startups to attract top scientific talent. However, companies frequently provide inadequate documentation of equity grants, fail to clearly communicate vesting terms and conditions, or make verbal promises about equity that aren’t reflected in written agreements.

Why It’s Dangerous: Equity disputes are increasingly common in the biotech space, particularly when companies are acquired or go public and suddenly equity has real value. Employees may claim they were promised more shares than documented, that vesting terms were different than written, or that the company failed to honor commitments.

Real Case Example: In 2018, a former Theranos COO was awarded $150,000 in a dispute over stock options, though the company’s collapse limited recovery. More significantly, in Bain v. ICON Health & Fitness (2020), a Utah court awarded nearly $1 million to an executive whose equity compensation was improperly documented and administered, finding the company breached its compensation agreement.

According to a 2023 study by Cooley LLP, equity compensation disputes in the life sciences sector have increased 47% since 2019, with median settlement values around $175,000 for individual claims and much higher for class actions.

The Solution: Treat equity compensation with the same rigor you’d apply to any other contractual relationship. Ensure every equity grant is documented through proper board approval and formal grant agreements that comply with IRC Section 409A regulations. Clearly communicate vesting schedules, acceleration provisions, and conditions that might affect equity. When discussing equity with candidates or employees, follow up verbal conversations with written confirmations. The goal is to eliminate ambiguity before it becomes conflict.

Moving Forward: Building Compliant HR Infrastructure

These five mistakes share a common theme: they often result from under-investing in HR infrastructure during the early stages when scientific and regulatory challenges feel more urgent. However, the cost of fixing employment law problems after they emerge almost always exceeds the cost of prevention.

According to Hiscox’s 2023 Employee Lawsuit Report, the average cost to defend an employment lawsuit is $160,000, with cases taking an average of 318 days to resolve. For startups racing toward milestones or fundraising deadlines, this represents both significant cash burn and devastating management distraction.

As your biotech startup grows, consider these proactive steps:

Conduct an employment law audit when you reach 15-20 employees or raise a significant funding round. An experienced employment attorney can review your practices and documentation to identify vulnerabilities before they become lawsuits.

Invest in fractional or part-time HR expertise earlier than you think you need it. Strategic HR support can help you navigate the unique challenges of managing scientific staff while ensuring compliance, without the overhead of a full-time executive hire.

Create template documents and processes for common situations: offer letters, equity grant agreements, performance review forms, and accommodation request procedures. Having these ready prevents last-minute decisions that create legal risk.

Train your managers on employment law basics. Scientists often become team leaders without management training. A few hours of education on documentation, accommodation obligations, and avoiding discrimination can prevent costly mistakes.

Get Expert Guidance from BackPocket Talent

The biotech industry moves fast, but employment law doesn’t forgive shortcuts. The five mistakes outlined above represent millions of dollars in avoidable legal exposure, not to mention the management distraction and reputational damage that comes with employment disputes.

At BackPocket Talent, we specialize in helping startups build compliant HR foundations without the overhead of full-time HR executives. While we’re expanding our practice into the biotech sector, we bring deep employment law expertise and proven systems for growing companies navigating these exact challenges. Our fractional HR model gives you senior-level strategic guidance precisely when you need it, whether that’s conducting compliance audits, creating proper documentation systems, handling complex accommodation requests, or ensuring your equity compensation practices protect both your company and your team.

We understand that biotech founders need to focus on science, fundraising, and getting to market. Our role is to handle the HR complexity so you can focus on what matters most, without the six-figure salary commitment of a full-time HR executive. We work alongside your leadership team to implement practical, scalable solutions that grow with your company from seed stage through Series B and beyond.

Ready to protect your biotech startup from costly employment law mistakes? Contact BackPocket Talent for a complimentary compliance assessment. We’ll review your current practices, identify potential vulnerabilities, and provide a roadmap for building HR infrastructure that supports your growth without slowing you down.

---

Sources and References

• U.S. Department of Labor, Fair Labor Standards Act Advisor
• California Labor Code Section 2870
• EEOC ADA Enforcement Guidance, “Reasonable Accommodation and Undue Hardship”
• Society for Human Resource Management (SHRM), “Managing Employee Performance Documentation”
• Hiscox, “2023 Guide to Employee Lawsuits”
• Cooley LLP, “Life Sciences Equity Compensation Report 2023”
• Case citations: Edwards v. Arthur Andersen LLP, 44 Cal. 4th 937 (2008); Bain v. ICON Health & Fitness, Utah Court of Appeals (2020)
• EEOC settlement and litigation data (publicly available press releases)
• Internal Revenue Code Section 409A regulations